“A Comprehensive Evaluation of the Transition to a Biosimilar of Adalimumab in Rheumatoid Arthritis and Psoriatic Arthritis: A Single-Center Experience With a Focus on Imaging Outcomes”. 2025. Reumatismo, May. https://doi.org/10.4081/reumatismo.2025.1748.